All AbMole products are for research use only, cannot be used for human consumption.

Cabazitaxel (Jevtana) is a semi-synthetic derivative of a natural taxoid. Cabazitaxel (Jevtana) increases CYP3A enzyme activities in rat hepatocytes. The mean ex-vivo human plasma protein binding of Cabazitaxel (Jevtana) is 91.6%. Cabazitaxel (Jevtana) is rapidly and extensively metabolised into numerous metabolites. Cabazitaxel (Jevtana) demonstrates activity in several murine and human resistant cell lines. With a 4-day exposure to cabazitaxel, cytotoxicity is noted with relatively low cabazitaxel concentrations. Cabazitaxel (Jevtana) shows high antitumor activity in 3 human colorectal cell lines (HCT-116, HCT-8, and HT-29). In accompanying models, Cabazitaxel (Jevtana) has significant antitumor activity. In murine tumor xenografts (colon C38 and pancreas P03), Cabazitaxel (Jevtana) causes complete tumor regressions. Using SF-295 and U251 human glioblastoma cell lines, both orthotopic and subcutaneous murine xenografts are generated. Cabazitaxel (Jevtana) treatment leads to complete regression in the majority of subcutaneously implanted tumors. Cabazitaxel (Jevtana) has entered in a phase I clinical trial in the treatment of solid cancer. Cabazitaxel (Jevtana) plus Prednisone, Carboplatin has entered in a phase II clinical trial in the treatment of prostate cancer. Cabazitaxel is a semi-synthetic derivative of a natural taxoid.
| Cell Experiment | |
|---|---|
| Cell lines | MCF-7 cells |
| Preparation method | Parallel drug selections were initiated using 0.1 nmol/L cabazitaxel, a concentration that would inhibit growth in MCF-7 cells by 50% (IC50 value) with and without 2 μmol/L PSC-833. Selections continued by increasing the drug concentration in a stepwise manner up to a final concentration of 5 nmol/L cabazitaxel. |
| Concentrations | 5 nmol/L |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | Male nude mice |
| Formulation | 1% medium /0.1% Tween-20 |
| Dosages | 30 mg/kg |
| Administration | i.v. |
| Molecular Weight | 835.93 |
| Formula | C45H57NO14 |
| CAS Number | 183133-96-2 |
| Solubility (25°C) | DMSO 90 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Duran GE, et al. Mol Cancer Ther. Mechanisms of resistance to cabazitaxel.
| Related Products |
|---|
| Lactate calcium
Lactate calcium is an excellent calcium fortifier that works better than inorganic calcium. Lactate calcium is used as an antacid. |
| Coniferyl ferulate
Coniferyl ferulate is a potent glutathione S-transferase (GST) inhibitor that reverses multidrug resistance and down-regulates p-glycoprotein. Coniferyl ferulate strongly inhibited human placental glutathione S-transferase with IC50 of 0.3 μM. |
| NXY-059
NXY-059 is a free radical-trapping neuroprotectant that has been reported to reduce infarct size and preserve brain function in experimental models of acute ischemic stroke. |
| Tie2 kinase inhibitor
Tie2 kinase inhibitor is a potent, reversible, and ATP-binding site-targeting Tie2 inhibitor with an IC50 of 250 nM. |
| Calcium levofolinate
Calcium levofolinate is a calcium salt of folinic acid that is an adjuvant used in cancer chemotherapy. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
